The MarketWatch News Department was not involved in the creation of this content.

February 15, 2021 (ACCESSWIRE via COMTEX) —
NEW YORK, NY / ACCESSWIRE / February 15, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.

bluebird bio, Inc. (NASDAQ:BLUE)

CONTACT JAKUBOWITZ ABOUT BLUE:

https://claimyourloss.com/securities/bluebird-bio-inc-loss-submission-form/?id=12894&from=1

Class Period : May 11, 2020 – November 4, 2020

Lead Plaintiff Deadline : April 13, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) data supporting bluebird’s BLA submission for LentiGlobin for SCD was insufficient to demonstrate drug product comparability; (ii) Defendants downplayed the foreseeable impact of disruptions related to the COVID-19 pandemic on the Company’s BLA submission schedule for LentiGlobin for SCD, particularly with respect to manufacturing; (iii) as a result of all the foregoing, it was foreseeable that the Company would not submit the BLA for LentiGlobin for SCD in the second half of 2021; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Tricida, Inc. (NASDAQ:TCDA)

CONTACT JAKUBOWITZ ABOUT TCDA:

https://claimyourloss.com/securities/tricida-inc-loss-submission-form/?id=12894&from=1

Class Period : September 4, 2019 – October 28, 2020

Lead Plaintiff Deadline : March 8, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Tricida’s NDA for veverimer was materially deficient; (ii) accordingly, it was foreseeably likely that the FDA would not accept the NDA for veverimer; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Bit Digital, Inc. (NASDAQ:BTBT)

CONTACT JAKUBOWITZ ABOUT BTBT:

https://claimyourloss.com/securities/bit-digital-inc-loss-submission-form/?id=12894&from=1

Class Period : December 21, 2020 – January 8, 2021

Lead Plaintiff Deadline : March 22, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) that Bit Digital overstated the extent of its a bitcoin mining operation; and (2) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Image: https://claimyourloss.com/wp-content/uploads/2021/01/tj_logo_bluegrey.png

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

JAKUBOWITZ LAW

1140 Avenue of the Americas

9th Floor

New York, New York 10036

T: (212) 867-4490

F: (212) 537-5887

SOURCE: Jakubowitz Law

View source version on accesswire.com:

https://www.accesswire.com/629788/LAWSUITS-FILED-AGAINST-BLUE-TCDA-and-BTBT–Jakubowitz-Law-Pursues-Shareholders-Claims

COMTEX_381092573/2457/2021-02-15T12:49:06

Is there a problem with this press release? Contact the source provider Comtex at [email protected]. You can also contact MarketWatch Customer Service via our Customer Center.

Copyright 2021 ACCESSWIRE

The MarketWatch News Department was not involved in the creation of this content.

Source